Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer

Phase 1/2 Completed 32 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI) · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying the best dose of sirolimus and to see how well it works before surgery in treating patients with advanced localized prostate cancer.

Timeline

Start: 2006-08
Primary completion: 2008-01
Completion: 2010-06

Publications

Results Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, De Marzo AM, Carducci MA. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010 Jun 1;16(11):3057-66. doi: 10.1158/1078-0432.CCR-10-0124. Epub 2010 May 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sirolimus	Small molecule	3 mg	Oral
Subject	Sirolimus	Small molecule	6 mg	Oral

Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications